Search clinical trials for: Fibroblast growth factor

Total 41860 results

QED Therapeutics, Inc.

Recruiting

Prospective Clinical Assessment Study in Children With Hypochondroplasia (HCH)

Hypochondroplasia

United States, Australia, Norway, Portugal, Singapore, Spain
Tri-Service General Hospital
Eusol Biotech Co., Ltd.

Not yet recruiting

The Effect and Safety of Recombinant Fibroblast Growth Factor-1 for Carpal Tunnel Syndrome

Carpal Tunnel Syndrome
Chiang Mai University

Not yet recruiting

Low-intensity Physical-cognitive Exercise and Cognitive Function

Mild Cognitive Impairment

Thailand
Tyra Biosciences, Inc

Recruiting

Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)

Solid Tumor | Intrahepatic Cholangiocarcinoma | Metastatic Cholangiocarcinoma | Locally Advanced Cholangiocarcinoma

United States
Tasly Biopharmaceuticals Co., Ltd.

Recruiting

A Trial to Evaluate the Safety Tolerability and Pharmacokinetics of B1344 by Subcutaneous Injection in Healthy Subjects

Nonalcoholic Steatohepatitis

United States
Janssen Pharmaceutical K.K.

Recruiting

A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer (TAR-210)

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Japan
Tyra Biosciences, Inc

Recruiting

Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations (SURF301)

Solid Tumor | Bladder Cancer | Advanced Solid Tumor | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Solid Tumor, Adult | FGFR3 Gene Mutation | Urinary Tract Cancer | Locally Advanced Urothelial Carcinoma | Advanced Urothelial Carcinoma | Non-muscle-invasive Bladder Cancer | FGFR3 Gene Alteration | Urinary... and other conditions

Australia, United States, France, Spain
Shen Qu

Recruiting

Prolactin and FGF21 in Gestational Diabetes Mellitus

Gestational Diabetes Mellitus in Pregnancy | Hyperprolactinemia Pregnancy

China
Amgen

Recruiting

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-301)

Solid Tumors

Canada, Korea, Republic of, Australia, Netherlands, United States, Israel, Austria, Spain, United Kingdom, France, Belgium, Japan, Czechia, Hungary, Poland, Brazil, Italy, Argentina, Denmark, Greece, Mexico, Switzerland, Romania, Finland and more
Janssen Research & Development, LLC

Recruiting

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

Urinary Bladder Neoplasms | Receptors, Fibroblast Growth Factor

Korea, Republic of, United States, Germany, Spain, Netherlands
Assistance Publique - Hôpitaux de Paris
Fondation Université de Paris

Not yet recruiting

Fibroblast Growth Factor 23 in Chronic Respiratory Failure (EFIC-RES)

Chronic Respiratory Failure
University Hospital Inselspital, Berne
Czech Technical University in Prague

Recruiting

REducing SPEECH-related Side-effects of Deep Brain Stimulation in Parkinson's Disease Via Automated Speech Analysis (RESPEECH-PD)

Parkinson Disease

Switzerland, Czechia
University Hospital Inselspital, Berne
University Hospital, Geneva; Ecole Polytechnique Fédérale de Lausanne

Recruiting

Psychological Effects of Levodopa in Parkinson's Disease

Parkinson Disease

Switzerland
Amgen
Zai Lab (China only)

Recruiting

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Canada, Japan, United States, Korea, Republic of, China, Italy, Australia, Sweden, Spain, Taiwan, France, Belgium, Denmark, Thailand, Turkey, Czechia, Bulgaria, Brazil, Norway, Mexico, Poland, Estonia, Israel, Greece, Romania, Chile, Peru, Po... and more
LianBio LLC

Recruiting

Infigratinib in Subjects With GC or GEJ With FGFR2 Amplification or Other Solid Tumors With Other FGFR Alterations (FGFR)

Gastric Cancer | Solid Tumor | Gastroesophageal Junction Adenocarcinoma

China
NYU Langone Health

Recruiting

Fibroblast Growth Factor Regeneration of Tympanic Membrane Perforations

Tympanic Membrane Perforation

United States
Wake Forest University Health Sciences
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE) (PHRASE)

Kidney Diseases | Hypertension | Pediatric Obesity | Proteinuria | Albuminuria | Kidney Injury | Blood Pressure Disorders | Autonomic Dysfunction | Pediatric Kidney Disease | Left Ventricular Dysfunction | Left Ventricular Hypertrophy | Kidney Dysfunction | Autonomic Imbalance | Left Ventricular Diastolic Dysfunction and other conditions

United States
Duke University
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) (POPS or POP02)

Heart Failure | Pain | Pneumonia | Hypertension | Edema | Hemophilia | Insomnia | Pulmonary Arterial Hypertension | Coagulation Disorder | Asthma in Children | Down Syndrome | Attention Deficit Hyperactivity Disorder | Bronchopulmonary Dysplasia | Hypokalemia | Hyperphosphatemia | Primary Hyperaldosteronism | Adrenal Insufficiency and other conditions

United States, Canada
QED Therapeutics, Inc.

Recruiting

Study of Infigratinib in Children With Achondroplasia

Achondroplasia

United States, Spain, United Kingdom, France, Canada, Australia
Second Affiliated Hospital, School of Medicine,...
Nantong University; Taizhou Hospital; The Second Affiliated Hospital of Kunming... and other collaborators

Recruiting

Clinical Study of Kangfuxin and Basic Fibroblast Growth Factor in Promoting the Healing of Donor Site

Wound Healing | Fibroblast Growth Factors

China
QED Therapeutics, Inc.

Recruiting

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

Achondroplasia

United States, Spain, Singapore, Canada, United Kingdom, France, Australia, Norway, Argentina, Germany, Italy
University of Colorado, Denver
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Recruiting

COMT Inhibition Among Individuals With Comorbid AUD/ADHD

Attention Deficit Hyperactivity Disorder | Alcohol Use Disorder

United States
First Affiliated Hospital, Sun Yat-Sen University

Recruiting

Fibroblast Growth Factor 23 and Hypertensive Disorder Complicating Pregnancy

Hypertension, Pregnancy-Induced

China
Incyte Corporation

Recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302)

Metastatic Cholangiocarcinoma | Unresectable Cholangiocarcinoma

United States, Canada, Belgium, France, Germany, Italy, China, Spain, Japan, United Kingdom, Netherlands, Switzerland, Austria, Denmark, Finland, Ireland, Israel, Norway, Sweden
Washington University School of Medicine
National Center for Advancing Translational Sciences (NCATS)

Recruiting

A Role for FGF21 in Postprandial Nutrient Homeostasis After RYGB (FGB)

Obesity

United States
University Hospital, Montpellier

Recruiting

Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients

Chronic Kidney Disease

France
University Hospital, Montpellier

Recruiting

New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients

Chronic Kidney Disease

France
CardioVascular BioTherapeutics, Inc.

Not yet recruiting

Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease

Myocardial Ischemia | Coronary Disease | Coronary Heart Disease | Coronary Arteriosclerosis
National Institute of Diabetes and Digestive and...

Completed

Acute Effects of Canagliflozin, a Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor on Bone Metabolism in Healthy Volunteers

Healthy Volunteers

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations (RAGNAR)

Advanced Solid Tumor

France, United States, Japan, Belgium, United Kingdom, Germany, Korea, Republic of, Taiwan, China, Poland, Italy, Spain, Australia, Brazil, Argentina
Janssen Research & Development, LLC

Active, not recruiting

A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)

Urothelial Cancer

Korea, Republic of, United States, Italy, Spain, Japan, United Kingdom, Belgium, Israel, China, Austria, France, Canada, Taiwan, Turkey, Germany, Russian Federation, Bulgaria, Poland, Greece, Brazil, Netherlands, Australia, Argentina, Mexic... and more
QED Therapeutics, Inc.

Enrolling by invitation

Extension Study of Infigratinib in Children With Achondroplasia (ACH)

Achondroplasia

United States, Spain, United Kingdom, France, Australia, Canada
University of California, Berkeley
University of California, San Francisco; Lawrence Berkeley National Laboratory

Completed

Dopaminergic Mechanisms Underlying Human Social Behavior

Executive Function | Decision Making | Dopamine

United States
QED Therapeutics, Inc.

Enrolling by invitation

A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia (PROPEL3)

Achondroplasia

Australia, United States, Argentina, Canada, France, Germany, Italy, Norway, Singapore, Spain, United Kingdom
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
Yonsei University

Completed

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

Korea, Republic of
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

FGFR2 Gene Mutation | Advanced Cholangiocarcinoma

Korea, Republic of, United States, Belgium, Spain, Taiwan, China, United Kingdom, France, Canada, Germany, Thailand, Italy, Portugal, Australia, Puerto Rico
Kyowa Kirin, Inc.
Kyowa Kirin Co., Ltd.

Completed

Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH)

X-linked Hypophosphatemia

Netherlands, United States, United Kingdom, France
Basilea Pharmaceutica

Terminated

Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma (FIDES-03)

Gastric Adenocarcinoma

Spain, United States, Korea, Republic of, Belgium, Russian Federation, United Kingdom, Italy, France, Turkey, Germany, Poland, Brazil, Australia, Argentina, Chile
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
National Institute of Dental and Craniofacial Research...

Active, not recruiting

Burosumab for Fibroblast Growth Factor-23 Mediated Hypophosphatemia in Fibrous Dysplasia

Fibrous Dysplasia Of Bone

United States
QED Therapeutics, Inc.
Helsinn Healthcare SA

Terminated

Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF302)

Upper Tract Urothelial Carcinomas | Urothelial Bladder Cancer

United States, France, Canada, Spain, Italy, Belgium, Germany, Netherlands, United Kingdom, Bulgaria, Greece
Ultragenyx Pharmaceutical Inc
Kyowa Kirin Co., Ltd.

Active, not recruiting

X-linked Hypophosphatemia Disease Monitoring Program

X-linked Hypophosphatemia | Hypophosphatemic Rickets

United States, Brazil, Argentina, Canada, Chile, Colombia
National Cancer Institute (NCI)

Active, not recruiting

Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Metastatic Gastrointestinal Stromal Tumor | Metastatic Sarcoma | Locally Advanced Sarcoma | Locally Advanced Gastrointestinal Stromal Tumor | Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8 | Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal... and other conditions

United States
Aristotle University Of Thessaloniki

Completed

FGF-21 Levels and RMR in Children and Adolescents With Hashimoto's Thyroiditis (THYROMETABOL) (THYROMETABOL)

Hashimoto Disease

Greece
National Cancer Center, Japan
Eisai Co., Ltd.

Active, not recruiting

NCCH2006/MK010 Trial (FORTUNE Trial)

Advanced or Recurrent Solid Tumors | FGFR Gene Alterations

Japan
Northwestern University
National Cancer Institute (NCI); Boehringer Ingelheim; Robert H. Lurie Cancer...

Active, not recruiting

Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A | Fibroblast Growth Factor Basic Form Measurement | FLT3 Internal Tandem Duplication

United States
Incyte Corporation

Completed

Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)

Non-Small Cell Lung Cancer (NSCLC)

Spain, United States, Italy, Germany, France
Eisai Co., Ltd.

Active, not recruiting

A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer

Breast Neoplasms

Japan
Eisai Co., Ltd.

Active, not recruiting

A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion

Cholangiocarcinoma

China, Japan

Search clinical trials for: Fibroblast growth factor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations